By Benjamin Chiou
Date: Monday 05 Jan 2026
(Sharecast News) - Pharma giant GSK has received regulatory approval in China for its Nucala treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD).
| Director/PDMR Shareholding | 22-Dec-2025 | ShareCast |
| GSK to lower drug prices and expand access in US | 22-Dec-2025 | ShareCast |
| Transaction in Own Shares | 22-Dec-2025 | ShareCast |
| Transaction in Own Shares | 19-Dec-2025 | ShareCast |
| GSK asthma treatment approved by US regulators | 17-Dec-2025 | ShareCast |
| Nucala for adults with COPD approved in China | 05-Jan-2026 | 07:00 | RNS |
| Director/PDMR Shareholding | 22-Dec-2025 | 15:30 | RNS |
| Director/PDMR Shareholding | 22-Dec-2025 | 15:30 | RNS |
| GSK to lower drug prices and expand access in US | 22-Dec-2025 | 07:00 | RNS |
| Transaction in Own Shares | 22-Dec-2025 | 07:00 | RNS |
| GlaxoSmithKline scraps sale of old drugs | 05-Dec-2014 | Telegraph |
| Glaxo sharpens axe to save £1bn as insurers and ... | 01-Dec-2014 | The Independent |
| GSK to cut hundreds of US jobs | 01-Dec-2014 | Telegraph |
| Ebola vaccine trials 'encouraging', says GSK | 27-Nov-2014 | Telegraph |
| GlaxoSmithKline tops table in effort to get drug... | 17-Nov-2014 | Guardian |
| Questor :GlaxoSmithKline | 16-Apr-2014 | Telegraph |
| Questor:GlaxoSmithKline | 06-Oct-2011 | Telegraph |
| Questor:GlaxoSmithKline | 11-Aug-2011 | Telegraph |
| Questor tip: GlaxoSmithKline | 28-Jul-2011 | Telegraph |
| Investment Column: GlaxoSmithKline | 27-Jul-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 1,829.00p |
| Change Today | -2.50p |
| % Change | -0.14 % |
| 52 Week High | 1,848.50p |
| 52 Week Low | 1,264.00p |
| Volume | 742,509 |
| Shares Issued | 4,075.43m |
| Market Cap | £74,540m |
| Beta | 0.99 |
| RiskGrade | 129 |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| Strong Buy | 4 |
| Buy | 3 |
| Neutral | 14 |
| Sell | 2 |
| Strong Sell | 0 |
| Total | 23 |

| Latest | Previous | |
|---|---|---|
| Q3 | Q2 | |
| Ex-Div | 13-Nov-25 | 14-Aug-25 |
| Paid | 08-Jan-26 | 09-Oct-25 |
| Amount | 16.00p | 16.00p |
| Time | Volume / Share Price |
| 13:06 | 0 @ 1,829.50p |
| 13:06 | 1 @ 1,828.50p |
| 13:06 | 0 @ 1,829.50p |
| 13:06 | 946 @ 1,829.00p |
| 13:06 | 5 @ 1,828.50p |
You are here: research